The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.
Saved in:
| Title: | The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. |
|---|---|
| Authors: | Kudo-Saito C; Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp., Imazeki H; Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Nagashima K; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan., Shoji H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Tsugaru K; Division of Gastroenterology and Hepatology, Keio University Hospital, Tokyo, Japan., Takahashi N; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan., Kawakami T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Amanuma Y; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan., Wakatsuki T; Department of Gastrointestinal Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan., Nagashima F; Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan., Narita Y; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Yamamoto Y; Department of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan., Kizawa R; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Boku N; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Medical Oncology and General Medicine, IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Nov 18; Vol. 74 (12), pp. 379. Date of Electronic Publication: 2025 Nov 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-025-04239-1 |
